METABOLIC DISORDERS
Increase in BMD with zoledronic acid in elderly women with osteoporosis and living in LTC
This report has been verified
by one or more authors of the
original publication.
JAMA Intern Med. 2015 Jun;175(6):913-21
181 elderly women with osteoporosis or bone fractures were randomized to receive either one 5-mg dose of zoledronic acid or placebo intravenously. The purpose of this study was to determine whether zoledronic acid was safe and effective for improving bone mineral density in frail elderly women with osteoporosis. Hip and spine bone mineral density were measured at 12 and 24 months post-intervention via dual x-ray absorptiometry. Results demonstrated significantly greater improvement in hip and spine bone mineral density, as well as bio-markers of bone resorption, in the zoledronic acid group compared to the placebo group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
